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Abstract
Diabetic nephropathy is the commonest cause of end-stage renal disease in
most developed economies. Current standard of care for diabetic nephropathy
embraces stringent blood pressure control via blockade of the
renin-angiotensin-aldosterone system and glycemia control. Recent
understanding of the pathophysiology of diabetic nephropathy has led to the
development of novel therapeutic options. This review article focuses on
available data from landmark studies on the main therapeutic approaches and
highlights some novel management strategies.
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Introduction
Diabetic nephropathy (DN) affects approximately one-third of 
individuals with diabetes mellitus (DM) and carries with it con-
siderable cardiovascular morbidity and mortality. Despite modern 
management of DM, the prevalence of this clinical entity continues 
to increase in association with an escalating diabetic population 
and, surprisingly, the excess mortality risk of DM is practically 
exclusively correlated with the occurrence of DN. Realistically, 
finding therapeutic modalities to stem this inexorable tide hinges 
upon a thorough understanding of the pathogenetic mechanisms 
leading to DN.
Recent evidence shows that DN comprises a heavy inflammatory 
element triggered by metabolic disorders, protein overload, and 
hemodynamic abnormalities1–3. Although traditionally viewed to be 
glomerular in origin, emerging data suggest that the tubular epi-
thelial cell plays an important role in orchestrating renal inflam-
mation in DN. The activation of NF-κB and pro-inflammatory 
chemokines/cytokines in tubular epithelial cells were associated 
with the extent of the proteinuria and interstitial cell infiltration4. 
Targeting some of NF-κB-related inflammatory molecules may 
have therapeutic potential. For instance, blocking CCL2 has shown 
promise in preliminary clinical trials and will be discussed below. 
Another potentially important mediator of metabolic inflamma-
tion during DN is the Toll-like receptor (TLR). Overexpression 
of TLR2 and TLR4 in monocytes is positively correlated with 
hemoglobin A1c (HbA1c) levels in diabetic patients5, and TLR4 
is also expressed in the renal tubules of human kidney biopsies of 
DN6. As blockade of TLR signaling has not yet been developed 
for clinical application, it will not be further discussed. Herein, we 
review the established therapeutic armamentarium and the progress 
in this emerging field, highlighting some novel management 
strategies arising from recent understanding of the mechanistic 
pathways leading to DN.
Current standard of approach to diabetic nephropathy
Glycemic optimization
Extended observations from the EDIC (Epidemiology of Diabetes 
Interventions and Complications) study on the original Diabetes 
Control and Complications Trial cohort of type 1 diabetics clearly 
demonstrated a legacy effect of early intensive diabetic control 
beyond 18 years, with an overall risk reduction of 44% in developing 
chronic kidney disease (CKD) with estimated glomerular filtration 
rate (eGFR) lower than 60 ml/min/1.73m27–9. For type 2 diabetics, 
the UK Prospective Diabetes Study (UKPDS)10 with follow-up of 
3,867 newly diagnosed patients showed that, compared with the 
conventional group (achieved HbA1c 7.9%), the risk in the inten-
sive group (HbA1c 7.0%) was 12% lower for any diabetes-related 
endpoint; 10% lower for any diabetes-related death; and 6% lower 
for all-cause mortality. The majority of the lowered risk in any 
diabetes-related aggregate endpoint was attributable to a 25% risk 
reduction in microvascular endpoints. More recently, the ADVANCE 
(Action in Diabetes and Vascular Disease: Preterax and Diamicron 
Modified Release Controlled Evaluation) trial, that included 11,140 
patients11, also demonstrated the value of tight glycemic control in 
terms of reduction of albuminuria (risk reduced by 9% and 30% 
for micro- and macro-albuminuria, respectively) and the risk of 
end-stage renal disease (ESRD, by 65%).
These encouraging data must be interpreted with caution, as reduc-
tion in albuminuria may be offset by the negative consequences of 
hypoglycemia from strict diabetic control. In the UKPDS10, patients 
in the intensive group had significantly more hypoglycemic episodes 
than those in the conventional group, regardless of whether data 
were analyzed by intent-to-treat or actual therapy. The ACCORD 
(Action to Control Cardiovascular Risk in Diabetes) trial was ter-
minated early due to excess mortality in the intensive therapy arm 
(HbA1c target <6.0%) versus the standard arm (HbA1c 7.0–7.9%)12. 
Likewise, severe hypoglycemia observed in the ADVANCE cohort 
was linked to a range of adverse clinical effects, which prompted 
speculation on what constitutes optimal diabetic control13.
The American Association of Clinical Endocrinologists recom-
mends an HbA1c target of <6.5%, while the American Diabetes 
Association sets a goal of HbA1c <7%, aiming to strike a bal-
ance between the risk of hypoglycemia and the clear benefit of 
renoprotection14.
Blood pressure control: the renin-angiotensin system
In patients with DM, hypertension has long been known to be an 
independent, modifiable variable which predisposes individuals to 
the development and acceleration of micro- and macro-vascular 
problems. Prospective observational data from UK Prospective 
Diabetes Study 36 showed that, for every 10 mmHg reduction in 
systolic blood pressure, there was a decrease in all DM-related com-
plications and death by 12% and 15%, respectively15. This is echoed 
by post-hoc analyses of 1,513 type 2 DM patients with confirmed 
DN and hypertension in the RENAAL (Reduction of Endpoints 
in NIDDM with the Angiotensin II Antagonist Losartan) trial that 
demonstrated that the risk of ESRD or death was raised by 6.7% for 
each 10 mmHg increase in baseline systolic blood pressure16.
Blockade of the renin-angiotensin system (RAS) using angiotensin-
converting enzyme inhibitors (ACEi) or angiotensin II receptor 
blockers (ARB) is superior to using other anti-hypertensive agents 
in DN. They provide other renoprotective benefits beyond simply 
regulation of blood pressure, which are apparent from the results of 
the MARVAL (Micro-Albuminuria Reduction with Valsartan) study. 
For any given level of blood pressure reduction, after 24 weeks 
valsartan was shown to perform better than amlodipine in reducing 
micro-albuminuria (56% compared to 92% from baseline) in 332 
type 2 DM individuals17. Treatment with ACEi was found to restrict 
development to macro-albuminuria by 60% in a meta-analysis of 
698 non-hypertensive type 1 DM patients with micro-albuminuria. 
Additionally, an increased odds ratio of 3.07 (95% confidence 
interval [CI] 2.15 – 4.44; P < 0.001) for regression to normo- 
albuminuria was demonstrated18. Moreover, a sub-study of the 
IRMA-2 (Irbesartan in Patients with Type 2 Diabetes and Micro-
albuminuria) trial showed that the reduction in micro-albuminuria 
by RAS blockade may persist, even after treatment withdrawal, 
which implies that glomerular structural normalization may be 
occurring19. In addition to the effects on micro-albuminuria, RAS 
blockade is equally effective in controlling macro-albuminuria20,21.
Ameliorating albuminuria forms an integral treatment goal to 
reduce hard renal endpoints for RAS blockade. Irbesartan was 
found to decrease the risk of serum creatinine doubling and 
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progression to ESRD by 33% and 23%, respectively, in the IDNT 
(Irbesartan Diabetic Nephropathy Trial) involving 1,715 hyperten-
sive type 2 DN patients and a mean follow-up of 2.6 years22. Similar 
observations have arisen from the post-hoc analyses of RENAAL, 
in which a 50% decrease in albuminuria after 6 months of losartan 
treatment correlated with a 45% decreased risk for ESRD at 4 years 
of follow-up23. These findings recapitulate the renoprotective effect 
of captopril in type 1 diabetics with overt nephropathy20.
There is little direct comparison between ACEi and ARB and they 
appear to have comparable efficacy in DN, although intractable dry 
cough may be associated with ACE inhibition. These findings are 
reinforced by the DETAIL (Diabetics Exposed to Telmisartan and 
Enalapril) trial, a randomized clinical trial (RCT) comparing tel-
misartan to enalapril in 250 type 2 DN patients. After 5 years, the 
degree of glomerular filtration rate (GFR) decline, albuminuria and 
ESRD incidence were no different between the study arms24.
It must be borne in mind that secondary prevention trials have so 
far provided all existing data for RAS blockade. In addition, the use 
of the dihydropyridine class of calcium channel blockers (CCB) 
in the control group in some of the RCTs, such as MARVAL (17), 
could be a potential confounder, as this class of CCB is known to 
increase afferent arteriolar vasodilation and therefore may aggra-
vate microalbuminuria in the control group. The National Kidney 
Foundation KDOQI clinical practice guidelines have not recom-
mended using ACEi or ARB for the primary prevention of DN in 
normotensive individuals with normo-albuminuria25.
Exploiting the renin-angiotensin-aldosterone axis
There is a theoretical pharmacologic basis for combining ACEi 
and ARB to maximize RAS blockade. In the CALM (Candesartan 
and Lisinopril Micro-albuminuria) study, a combination of cande-
sartan and lisinopril was shown to lower micro-albuminuria more 
effectively than either drug alone at 12 weeks26. However, longer 
follow-up studies were never able to reproduce these short-term 
results. Moreover, no trial has as yet clearly demonstrated a more 
favorable renal outcome with dual RAS blockade. The findings 
from one RCT—ONTARGET (Ongoing Telmisartan Alone and 
in Combination with Ramipril Global Endpoint Trial), in which 
ramipril, telmisartan or both were administered to 25,620 high 
vascular risk patients (37.5% diabetics)—question the use of dual 
blockade, as combination therapy was shown to increase the com-
posite outcome of dialysis, doubling of serum creatinine, and death 
(hazard ratio [HR] 1.09; 95% CI 1.01 – 1.18; P ≤ 0.037)27. The imme-
diate response from the renal community was that ONTARGET 
was likely to be off target28. More recently, however, VA 
NEPHRON-D (Veterans Affairs Nephropathy in Diabetes) looked 
at 1,448 type 2 DN patients with eGFR 30–89.9 mL/min/1.73m2 
treated with losartan alone or in combination with lisinopril29. After 
a median follow-up of just 2.2 years, the trial ended early due to no 
renal benefit being observed with dual therapy and an excessive risk 
of hyperkalemia (9.9% vs. 4.4%) and acute kidney injury (18% vs. 
11%). In DN patients with more advanced CKD, dual RAS inhibi-
tion would carry an even greater risk. In general, therefore, combi-
nation therapy cannot be advised for DN management.
Apart from combining ACEi and ARB, aldosterone antagonism 
may be another approach to complementing RAS blockade. In 
fact, meta-analyses have demonstrated that a supplement of a 
mineralocorticoid receptor antagonist (MRA) given to those 
treated with ACEi or ARB produces a decrease in proteinuria 
in the CKD population30. Such beneficial effects were likewise 
observed in DN cohorts following administration of non-selective 
(spironolactone)31–33 and selective (eplerenone)34 MRA. However, 
several of the studies exploring the use of aldosterone antagonism 
in combination with RAS inhibition found evidence for a greater 
risk of hyperkalemia.
Finerenone is a new nonsteroidal MRA with increased receptor 
selectivity compared to spironolactone and greater receptor affin-
ity than eplerenone in vitro, along with a less frequent occurrence 
of hyperkalemia than spironolactone35. In a recent trial36 that 
recruited patients with type 2 DM and urine albumin-to-creatinine 
ratio (UACR) above 30 mg/g, finerenone added to ACEi or ARB 
produced a dose-dependent decrease in UACR without induc-
ing hyperkalemia at day 90. The study had several impor-
tant limitations37. For example, 60% of participants had GFR 
>60 ml/min/1.73m2, and consequently had a greatly decreased 
risk of hyperkalemia when compared with participants that had 
more severe renal disease. Additionally, two-thirds of the patients 
were receiving loop or thiazide diuretics, which facilitate kaliure-
sis. Finally, only a small drop in blood pressure was observed in 
those having the highest dose of finerenone, contrasting with earlier 
reports showing that steroidal MRAs lower blood pressure when 
combined with other medications, including RAS blockers. This 
might indicate a different mechanism of action of steroidal and 
nonsteroidal MRAs.
Lipid Lowering Therapy
Statins are the most widely used class of drug for lipid lowering 
in individuals with type 2 diabetes, reflecting the indisputable 
evidence that lowering of LDL cholesterol in individuals with type 
2 diabetes is associated with reduced cardiovascular events and 
mortality. The role of lipid-lowering treatments in renoprotection 
for patients with diabetes, however, is debatable. In the Medical 
Research Council/British Heart Foundation (MRC/BHF) Heart 
Protection Study38, subgroup analysis for participants with diabe-
tes, allocation to simvastatin (40 mg/day) significantly decreased 
the rise in serum creatinine values. Subjects with late stage CKD 
were not studied, as those with serum creatinine >200 umol/L 
were excluded from the trial. On the other hand, allocation to sim-
vastatin plus ezetimibe in the Study of Heart and Renal Protec-
tion (SHARP)39 comprising 23% diabetic subjects did not produce 
significant reductions in any of the prespecified measures of renal 
disease progression among the subgroup of 6,247 nondialysis 
patients with a mean eGFR of 26.6 ml/min/1.73m2. Whether lipid 
lowering could only confer tangible renoprotection during early 
rather than late CKD requires further investigation.
In the Greek atorvastatin and coronary heart disease evaluation 
(GREACE)40 patients given atorvastatin had a significant reduction 
in urinary albumin excretion; however, separate analysis for type 
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2 diabetes was not included in the study. Such findings have been 
echoed recently by the PLANET I study41, in which treatment with 
atorvastatin 80 mg lowered UPCR substantially more than rosuvas-
tatin 10 mg (-15·6%, 95% CI -28·3 to -0·5; p=0·043) or rosuvastatin 
40 mg (-18·2%, -30·2 to -4·2; p=0·013). It must be cautioned that 
such doses of atorvastatin are unusually high for the average CKD 
patient.
Novel therapeutic modalities
Despite maximal RAS inhibition and other measures to control 
blood pressure and hyperglycemia, DN progression to ESRD 
remains intractable in many patients. Renewed understanding of 
the pathophysiology of DN has fueled the development of sev-
eral potentially promising novel therapeutic options, and these are 
summarized below.
Pleotropic renoprotective effects of anti-diabetic drugs 
beyond glycemic control
Certain hypoglycemic agents have been shown to confer inde-
pendent renoprotective effects beyond their hypoglycemic action. 
For instance, peroxisome proliferator activator receptor-gamma 
(PPAR-γ) agonists, also known as thiazolidinediones (TZD), have 
direct renoprotective effects in experimental models42. However, 
reports from clinical studies have been varied, with some achiev-
ing encouraging results by lowering proteinuria43–44, whilst some 
have demonstrated no meaningful effect45. Post-hoc analysis of the 
results of the PROactive (Prospective Pioglitazone Clinical Trial 
in Macro-vascular Events) study, which involved 5,238 DM sub-
jects with macro-vascular complications, even reported a larger 
decrease in eGFR with pioglitazone46. Amongst the confusion, 
a meta-analysis of 15 TZD trials (10 with pioglitazone; 5 with 
rosiglitazone) which enrolled 2,860 patients did show a significant 
decline in albuminuria47. Apart from these surrogate end-points, 
however, there is still no data to support the fact that TZDs may 
improve hard renal outcomes, and several safety concerns have 
now been raised regarding these drugs, including heightened cardi-
ovascular risks48,49 and malignancy50,51. With the current evidence, 
TZDs are unlikely to be a major player in the therapeutic armamen-
tarium for DN.
Glucagon-like peptide 1, an incretin which promotes insulin and 
suppresses glucagon release, is produced by the gut when food is 
ingested and it is degraded by dipeptidyl peptidase-4 (DPP-4)52. 
A novel group of hypoglycemic agents in the form of DPP-4 
inhibitors have emerged in the treatment paradigm of DM, and 
experimental models have indicated possible renoprotective 
benefits53,54. Currently, data has only been obtained from a few 
clinical trials; however, in small, uncontrolled studies, 6 months of 
sitagliptin55 or 12 weeks of alogliptin56 lowered albuminuria in 
patients with type 2 DM. These findings must be interpreted with 
caution, as the sample size was small and treatment had prompted 
HbA1c to be lowered appropriately. Thus, it is difficult to delineate 
the role of the improved glycemic control in the reduction of albu-
minuria. However, the results of four phase III studies, comprising 
217 patients with DN on RAS inhibition, indicated that 24 weeks of 
linagliptin significantly reduced albuminuria (32% reduction; 95% 
CI -42 to -21; P < 0.05), independent of HbA1c57. The encouraging 
findings regarding DPP-4 inhibitors, combined with their tolerabil-
ity, weight neutral benefit and low risk of hypoglycemia58,59 have 
triggered further research into the gut-renal axis as a possible focus 
of future treatments60. Indeed, numerous clinical trials are currently 
underway to explore incretin-based therapies for retarding the 
progression of DN.
Vitamin D receptor activators
Vitamin D receptor (VDR) activators demonstrated anti-inflam-
matory and anti-proteinuric effects in animal models of DN61,62. 
Findings from the phase III VITAL (Selective Vitamin D Receptor 
Activation with Paricalcitol for Reduction of Albuminuria in 
Patients with Type 2 Diabetes) trial indicate that adjuvant parical-
citol at 2 μg/day lowers residual albuminuria in DN63. However, 
42% of patients needed a reduced dose of paricalcitol due to poor 
tolerance, not to mention the additional drawback of the high cost 
of treatment. Therefore, concrete evidence demonstrating the suc-
cessful use of VDR activators to retard the progression of DN is 
still awaited.
Sodium-glucose cotransporter 2 inhibition
Apart from their ability to enhance urinary glucose excretion and 
aid glycemic control, SGLT-2 inhibitors appear to also promote an 
attractive cardiovascular portfolio that includes blood pressure and 
body weight optimization64–66. In the EMPA-REG study67 that has 
recruited over 7,000 type 2 diabetics at high cardiovascular risk, 
empagliflozin when added to standard care reduced the rates of 
death from cardiovascular causes (3.7%, vs. 5.9% in the placebo 
group; 38% relative risk reduction [RRR]), hospitalization for heart 
failure (2.7% and 4.1%, respectively; 35% RRR), and death from 
any cause (5.7% and 8.3%, respectively; 32% RRR). Unpublished 
data (presented at the American Society of Nephrology Kidney 
Week 2015 in San Diego) on renal outcomes are also promising, 
with significant reductions in new onset or worsening of nephropa-
thy and the composite renal endpoints of doubling of serum cre-
atinine, initiation of renal replacement therapy or death from renal 
cause.
Selective C-C chemokine receptor type 2 antagonism
Monocyte chemoattractant protein-1 (MCP-1), also called C-C 
chemokine ligand 2 (CCL2), one of the ligands for C-C chemokine 
receptor type 2 (CCR2), has been implicated not only in insulin 
resistance but also in progressive renal injury, and has been sug-
gested to be a potential marker of renal disease. In DN, MCP-1 
overexpression plays an indispensable role in promoting monocyte 
and macrophage migration and activation68. CCX140-B is a 
small molecule CCR2 antagonist that inhibits CCR2 and blocks 
MCP-1-dependent monocyte activation and chemotaxis. Data from 
preclinical studies suggested that oral CCX140-B improved glycae-
mia and albuminuria in a mouse model of diabetes69.
The first evidence that CCR2 inhibition lowers albuminuria in DN 
came from a recent European study70. Patients with type 2 DM aged 
18–75 years with UACR 100–3000 mg/g, eGFR ≥25 mL/min/1.73m2, 
and taking stable antidiabetic treatment and an ACEi or ARB for 
at least 8 weeks, were stratified to oral placebo, 5 mg CCX140-B, 
or 10 mg CCX140-B once a day. UACR changes from baseline 
during 52 weeks were -2% for placebo (95% CI -11% to 9%), 
-18% for 5 mg CCX140-B (-26% to -8%), and -11% for 10 mg 
CCX140-B (-20% to -1%). There was a -16% difference between 
5 mg CCX140-B and placebo and a -10% difference between 
Page 5 of 9
F1000Research 2016, 5(F1000 Faculty Rev):1044 Last updated: 31 MAY 2016
10 mg CCX140-B and placebo, without significant difference in 
adverse events or renal events during the study. The data suggest 
that CCR2 inhibition with CCX140-B has albumin-lowering effects 
on top of current standard of care in patients with DN. Translation 
into hard evidence in follow-up studies that test whether CCX140-B 
also limits progression to end-stage renal disease is needed.
Conclusion
Despite improved understanding of the pathophysiology of DN 
over the last 2 decades, an effective and specific treatment for 
this inexorable condition remains limited as the incidence of 
type 2 DM is predicted to continue an exponential upward tra-
jectory, particularly in the developing world. The clinician is still 
equipped with no more than merely RAS blockers for control of 
blood pressure, various hypoglycemic agents for optimizing blood 
glucose and perhaps statins for controlling hyperlipidemia. Large-
scale clinical trials that rode on the identification of emerging 
pathophysiologic pathways have met successes and tribulations 
[reviewed in reference 71] and we await the results of a number 
of further trials in the therapeutics of DN.
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